Target intelligence / Profile preview

Molecular chaperone MKKS (MKKS)

Target
MKKS
Molecular classification
Chaperonin (Group II chaperonin-like protein), Molecular chaperone, Centrosomal protein
01

Overview

Molecular chaperone MKKS is a Group II chaperonin-like protein predominantly localized at the pericentriolar material of centrosomes in human cells[5]. Its primary function is to assist in the proper folding of proteins using ATP hydrolysis and to promote the assembly of the BBSome complex, which is essential for ciliogenesis—the formation and function of primary cilia that mediate important signaling pathways[6][7]. MKKS is critical during early development, particularly in the formation of limbs, heart, and reproductive system, and participates in protein processing and intracellular transport, including the potential movement of key regulatory proteins (e.g., SMARCC1) to the nucleus[2][6]. Pathogenic mutations disrupt its chaperonin activity, cause mislocalization or aggregation at the centrosome, and underlie the genetic syndromes Bardet–Biedl syndrome and McKusick–Kaufman syndrome[1][5][6]. MKKS is not currently considered a direct therapeutic target—no small molecules or biologics are known to modulate its activity clinically[6][7].

Other names
BBS6Bardet-Biedl syndrome 6 proteinMcKusick-Kaufman/Bardet-Biedl syndromes putative chaperoninHMCSKMSMKS
02

Biological functions

Protein foldingChaperonin activityIntracellular transportCiliogenesisAssembly of BBSome complexCytokinesisEarly developmental processes (limb, heart, and reproductive system formation)
03

Disease associations

Congenital heart diseaseLimb malformationReproductive system disordersBardet–Biedl syndromeMcKusick–Kaufman syndromeObesityRetinal degenerationKidney dysfunction
04

Safety considerations

Mutations in MKKS lead to loss of protein function, mislocalization, protein aggregation, and increased susceptibility to disease phenotypes. Some mutations result in rapid degradation via the ubiquitin–proteasome pathway, which may contribute to cytotoxic accumulation of misfolded or aggregated protein in affected tissues[1][5].

Beyond the preview

Go deeper on Molecular chaperone MKKS (MKKS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular chaperone MKKS (MKKS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call